{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:44:46Z","timestamp":1793159086939,"version":"4.5.0"},"reference-count":175,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. However, there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review, meta-analysis, and overview of reviews to assess the incidence of psychedelic-induced psychosis and symptom exacerbation in schizophrenia. Our pre-registered protocol (CRD42023399591) covered: LSD, psilocybin, mescaline, DMT, and MDMA, using data from Embase, PubMed, PsyARTICLES, PsyINFO, and trial registries up to November 2023. A random-effects model was used to calculate psychosis incidence, with standardized assessments of study quality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From 131 publications, we analyzed 14 systematic reviews, 20 reviews, 35 randomized-controlled trials (RCTs), 10 case-control studies, 30 uncontrolled trials (UCTs), and 22 cohort studies, most of which were low quality. Meta-analysis of nine studies showed an incidence of psychedelic-induced psychosis at 0.002% in population studies, 0.2% in UCTs, and 0.6% in RCTs. In UCTs including individuals with schizophrenia, 3.8% developed long-lasting psychotic symptoms. Of those with psychedelic-induced psychosis, 13.1% later developed schizophrenia. Sensitivity analyses confirmed the results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In summary, the reviewed evidence suggests that schizophrenia might not be a definite exclusion criterion for clinical trials exploring safety and efficacy of psychedelics for treatment-resistant depression and negative symptoms. However, given the low quality and limited number of studies, more high-quality research is needed, and a conservative approach is recommended until further data is available.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41380-024-02800-5","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T19:23:10Z","timestamp":1732648990000},"page":"1223-1255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-5596","authenticated-orcid":false,"given":"Michel","family":"Sab\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Sulstarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alban","family":"Glangetas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"De Pieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Mallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-9425","authenticated-orcid":false,"given":"Logos","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0778-3728","authenticated-orcid":false,"given":"H\u00e9l\u00e9ne","family":"Richard-Lepouriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Penzenstadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Seragnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Thorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Zullino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0413-7672","authenticated-orcid":false,"given":"Katrin","family":"Preller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerem","family":"B\u00f6ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-7233","authenticated-orcid":false,"given":"Marco","family":"Solmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9486-1439","authenticated-orcid":false,"given":"Matthias","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"2800_CR1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.euroneuro.2022.09.004","volume":"64","author":"M Solmi","year":"2022","unstructured":"Solmi M, Chen C, Daure C, Buot A, Ljuslin M, Verroust V, et al. A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol. 2022;64:44\u201360.","journal-title":"Eur Neuropsychopharmacol J Eur Coll Neuropsychopharmacol"},{"key":"2800_CR2","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med. 2022;387:1637\u201348.","journal-title":"N Engl J Med"},{"key":"2800_CR3","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1134454","volume":"14","author":"PB van der Meer","year":"2023","unstructured":"van der Meer PB, Fuentes JJ, Kaptein AA, Schoones JW, de Waal MM, Goudriaan AE, et al. Therapeutic effect of psilocybin in addiction: a systematic review. Front Psychiatry. 2023;14:1134454.","journal-title":"Front Psychiatry"},{"key":"2800_CR4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.31486\/toj.23.0076","volume":"23","author":"L Feulner","year":"2023","unstructured":"Feulner L, Sermchaiwong T, Rodland N, Galarneau D. Efficacy and safety of psychedelics in treating anxiety disorders. Ochsner J. 2023;23:315\u201328.","journal-title":"Ochsner J"},{"key":"2800_CR5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/7854_2022_366","volume":"56","author":"AJ Khan","year":"2022","unstructured":"Khan AJ, Bradley E, O\u2019Donovan A, Woolley J. Psilocybin for trauma-related disorders. Curr Top Behav Neurosci. 2022;56:319\u201332.","journal-title":"Curr Top Behav Neurosci"},{"key":"2800_CR6","doi-asserted-by":"publisher","unstructured":"Aaronson ST, van der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, et al. Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized controlled trial. JAMA Psychiatry. 2023. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4685.","DOI":"10.1001\/jamapsychiatry.2023.4685"},{"key":"2800_CR7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00005053-198410000-00001","volume":"172","author":"RJ Strassman","year":"1984","unstructured":"Strassman RJ. Adverse reactions to psychedelic drugs. A review of the literature. J Nerv Ment Dis. 1984;172:577\u201395.","journal-title":"J Nerv Ment Dis"},{"key":"2800_CR8","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41380-022-01832-z","volume":"28","author":"G Wolf","year":"2023","unstructured":"Wolf G, Singh S, Blakolmer K, Lerer L, Lifschytz T, Heresco-Levy U, et al. Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation. Mol Psychiatry. 2023;28:44\u201358.","journal-title":"Mol Psychiatry"},{"key":"2800_CR9","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"F Vollenweider","year":"1999","unstructured":"Vollenweider F, Vollenweider-Scherpenhuyzen M, B\u00e4bler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1999;9:3897\u2013902.","journal-title":"Neuroreport"},{"key":"2800_CR10","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110263","volume":"109","author":"M Sab\u00e9","year":"2021","unstructured":"Sab\u00e9 M, Zhao N, Kaiser S. A systematic review and meta-analysis of the prevalence of cocaine-induced psychosis in cocaine users. Prog Neuro-Psychopharmacology Biol Psychiatry. 2021;109:110263.","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry"},{"key":"2800_CR11","doi-asserted-by":"crossref","first-page":"e072348","DOI":"10.1136\/bmj-2022-072348","volume":"382","author":"M Solmi","year":"2023","unstructured":"Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, et al. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023;382:e072348.","journal-title":"BMJ"},{"key":"2800_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/schbul\/16.1.81","volume":"16","author":"MB Bowers Jr.","year":"1990","unstructured":"Bowers MB Jr, Mazure CM, Nelson JC, Jatlow PI. Psychotogenic drug use and neuroleptic response. Schizophr Bull. 1990;16:81\u20135.","journal-title":"Schizophr Bull"},{"key":"2800_CR13","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/archpsyc.1966.01730170002002","volume":"15","author":"M Fink","year":"1966","unstructured":"Fink M, Simeon J, Haque W, Itil T. Prolonged adverse reactions to LSD in psychotic subjects. Arch Gen Psychiatry. 1966;15:450\u20134.","journal-title":"Arch Gen Psychiatry"},{"key":"2800_CR14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1176\/ajp.108.8.579","volume":"108","author":"PH Hoch","year":"1952","unstructured":"Hoch PH, Cattell JP, Pennes HH. Effects of Mescaline and Lysergic Acid (d-LSD-25). Am J Psychiatry. 1952;108:579\u201384.","journal-title":"Am J Psychiatry"},{"key":"2800_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/ajp.125.10S.1","volume":"125","author":"M Kramer","year":"1969","unstructured":"Kramer M. Cross-national study of diagnosis of the mental disorders: origin of the problem. Am J Psychiatry. 1969;125:1\u201311.","journal-title":"Am J Psychiatry"},{"key":"2800_CR16","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1176\/appi.ajp.2016.15081035","volume":"173","author":"B Helfer","year":"2016","unstructured":"Helfer B, Samara MT, Huhn M, Klupp E, Leucht C, Zhu Y, et al. Efficacy and safety of antidepressants added to antipsychotics for schizophrenia: a systematic review and meta-analysis. Am J Psychiatry. 2016;173:876\u201386.","journal-title":"Am J Psychiatry"},{"key":"2800_CR17","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","volume":"23","author":"C Ly","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics promote structural and functional neural plasticity. Cell Rep. 2018;23:3170\u201382.","journal-title":"Cell Rep"},{"key":"2800_CR18","doi-asserted-by":"crossref","unstructured":"Arnovitz MD, Spitzberg AJ, Davani AJ, Vadhan NP, Holland J, Kane JM, et al. MDMA for the treatment of negative symptoms in schizophrenia. J Clin Med. 2022;11:3255.","DOI":"10.3390\/jcm11123255"},{"key":"2800_CR19","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/02791072.1985.10524333","volume":"17","author":"S Cohen","year":"1985","unstructured":"Cohen S. LSD: the varieties of psychotic experience. J Psychoactive Drugs. 1985;17:291\u20136.","journal-title":"J Psychoactive Drugs"},{"key":"2800_CR20","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/schbul\/sbz102","volume":"46","author":"B Murrie","year":"2020","unstructured":"Murrie B, Lappin J, Large M, Sara G. Transition of substance-induced, brief, and atypical psychoses to schizophrenia: a systematic review and meta-analysis. Schizophr Bull. 2020;46:505\u201316.","journal-title":"Schizophr Bull"},{"key":"2800_CR21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/syn.20561","volume":"62","author":"P Seeman","year":"2008","unstructured":"Seeman P, Guan H-C. Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia. Synapse. 2008;62:819\u201328.","journal-title":"Synapse"},{"key":"2800_CR22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.euroneuro.2023.07.011","volume":"76","author":"N Perez","year":"2023","unstructured":"Perez N, Langlest F, Mallet L, De Pieri M, Sentissi O, Thorens G, et al. Psilocybin-assisted therapy for depression: a systematic review and dose-response meta-analysis of human studies. Eur Neuropsychopharmacol. 2023;76:61\u201376.","journal-title":"Eur Neuropsychopharmacol"},{"key":"2800_CR23","first-page":"381","volume":"11","author":"NS Mustafa","year":"2020","unstructured":"Mustafa NS, Bakar NHA, Mohamad N, Adnan LHM, Fauzi NFAM, Thoarlim A, et al. MDMA and the brain: a short review on the role of neurotransmitters in neurotoxicity. Basic Clin Neurosci. 2020;11:381\u20138.","journal-title":"Basic Clin Neurosci"},{"key":"2800_CR24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/hup.348","volume":"16","author":"ME Liechti","year":"2001","unstructured":"Liechti ME, Vollenweider FX. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol. 2001;16:589\u201398.","journal-title":"Hum Psychopharmacol"},{"key":"2800_CR25","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora G M, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y, et al. MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med. 2023;29:2473\u201380.","journal-title":"Nat Med"},{"key":"2800_CR26","doi-asserted-by":"crossref","first-page":"e000071","DOI":"10.1136\/bmjmed-2021-000071","volume":"1","author":"L Belbasis","year":"2022","unstructured":"Belbasis L, Bellou V, Ioannidis JPA. Conducting umbrella reviews. BMJ Med. 2022;1:e000071.","journal-title":"BMJ Med"},{"key":"2800_CR27","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.694863","volume":"12","author":"A Fiorentini","year":"2021","unstructured":"Fiorentini A, Cant\u00f9 F, Crisanti C, Cereda G, Oldani L, Brambilla P. Substance-induced psychoses: an updated literature review. Front Psychiatry. 2021;12:694863.","journal-title":"Front Psychiatry"},{"key":"2800_CR28","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.","journal-title":"BMJ"},{"key":"2800_CR29","doi-asserted-by":"crossref","DOI":"10.1186\/s41073-019-0064-8","volume":"4","author":"C Baethge","year":"2019","unstructured":"Baethge C, Goldbeck-Wood S, Mertens S. SANRA\u2014a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5.","journal-title":"Res Integr Peer Rev"},{"key":"2800_CR30","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"2800_CR31","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JAC Sterne","year":"2016","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.","journal-title":"BMJ"},{"key":"2800_CR32","unstructured":"OCEBM. The Oxford Levels of Evidence 2. OCEBM Levels Evid Work Gr. 2011. 2011."},{"key":"2800_CR33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","volume":"28","author":"R DerSimonian","year":"2007","unstructured":"DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28:105\u201314.","journal-title":"Contemp Clin Trials"},{"key":"2800_CR34","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"2800_CR35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. J Stat Softw. 2010;36:1\u201348.","journal-title":"J Stat Softw"},{"key":"2800_CR36","doi-asserted-by":"crossref","DOI":"10.1186\/s12874-021-01381-z","volume":"21","author":"TH Barker","year":"2021","unstructured":"Barker TH, Migliavaca CB, Stein C, Colpani V, Falavigna M, Aromataris E, et al. Conducting proportional meta-analysis in different types of systematic reviews: a guide for synthesisers of evidence. BMC Med Res Methodol. 2021;21:189.","journal-title":"BMC Med Res Methodol"},{"key":"2800_CR37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00005053-196001000-00005","volume":"130","author":"S Cohen","year":"1960","unstructured":"Cohen S. Lysergic acid diethylamide: side effects and complications. J Nerv Ment Dis. 1960;130:30\u201340.","journal-title":"J Nerv Ment Dis"},{"key":"2800_CR38","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1001\/archneurpsyc.1956.02330240026003","volume":"75","author":"NA Bercel","year":"1956","unstructured":"Bercel NA, Travis LEEE, Olinger LB, Dreikurs E, Polos MG. Model psychoses induced by LSD-25 in normals: I. Psychophysiological investigations, with special reference to the mechanism of the paranoid reaction. AMA Arch Neurol Psychiatry. 1956;75:588\u2013611.","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"2800_CR39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1176\/ajp.133.2.203","volume":"133","author":"JC Gillin","year":"1976","unstructured":"Gillin JC, Kaplan J, Stillman R, Wyatt RJ. The psychedelic model of schizophrenia: the case of N,N -dimethyltryptamine. Am J Psychiatry. 1976;133:203\u20138.","journal-title":"Am J Psychiatry"},{"key":"2800_CR40","unstructured":"R\u00fcmmele W, Gnirss F. Untersuchungen mit Psilocybin, einer psychotropen Subtanz aus Psilocybe Mexicana. Schweiz Arch Neurol Psychiatr. 1961;87:365\u201385."},{"key":"2800_CR41","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2020.100538","volume":"27","author":"BT Anderson","year":"2020","unstructured":"Anderson BT, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine. 2020;27:100538.","journal-title":"EClinicalMedicine"},{"key":"2800_CR42","first-page":"279","volume":"60","author":"WA Stoll","year":"1947","unstructured":"Stoll WA. Lysergs\u00e4ure-Di\u00e4thylamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiatr. 1947;60:279\u2013323.","journal-title":"Schweiz Arch Neurol Psychiatr"},{"key":"2800_CR43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0447.1949.tb04588.x","volume":"24","author":"G Condrau","year":"1949","unstructured":"Condrau G. Klinische erfahrungen an geisteskranken mit lysergs\u00e4ure-di\u00e4thylamid. Acta Psychiatr Scand. 1949;24:9\u201332.","journal-title":"Acta Psychiatr Scand"},{"key":"2800_CR44","unstructured":"Belsanti R. Modificazioni neuro-psico-biochimiche indotte dalla dietilamide dell\u2019acido lisergico in schizofrenici e frenastenici. Acta Neurol (Napoli). 1952;7:25."},{"key":"2800_CR45","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1192\/bjp.108.452.95","volume":"108","author":"G Anastasopoulos","year":"1962","unstructured":"Anastasopoulos G, Photiades H. Effects of LSD-25 on relatives of schizophrenic patients. J Ment Sci. 1962;108:95\u20138.","journal-title":"J Ment Sci"},{"key":"2800_CR46","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1001\/archneurpsyc.1951.02320050038004","volume":"65","author":"GR Forrer","year":"1951","unstructured":"Forrer GR, Goldner RD. Experimental physiological studies with lysergic acid diethylamide (LSD-25). AMA Arch Neurol Psychiatry. 1951;65:581\u20138.","journal-title":"AMA Arch Neurol Psychiatry"},{"key":"2800_CR47","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/jnnp.16.1.7","volume":"16","author":"DW Liddell","year":"1953","unstructured":"Liddell DW, Weil-Malherbe H. The effects of methedrine and of lysergic acid diethylamide on mental processes and on the blood andrenaline level. J Neurol Neurosurg Psychiatry. 1953;16:7\u201313.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2800_CR48","first-page":"84","volume":"5","author":"L Bender","year":"1963","unstructured":"Bender L, Faretra G, Cobrinik L. LSD and UML treatment of hospitalized disturbed children. Recent Adv Biol Psychiatry. 1963;5:84\u201392.","journal-title":"Recent Adv Biol Psychiatry"},{"key":"2800_CR49","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/archpsyc.1977.01770190094009","volume":"34","author":"MBJ Bowers","year":"1977","unstructured":"Bowers MBJ. Psychoses precipitated by psychotomimetic drugs. A follow-up study. Arch Gen Psychiatry. 1977;34:832\u20135.","journal-title":"Arch Gen Psychiatry"},{"key":"2800_CR50","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.4088\/JCP.12m07822","volume":"74","author":"JA Niemi-Pyntt\u00e4ri","year":"2013","unstructured":"Niemi-Pyntt\u00e4ri JA, Sund R, Putkonen H, Vorma H, Wahlbeck K, Pirkola SP. Substance-induced psychoses converting into schizophrenia. J Clin Psychiatry. 2013;74:e94\u2013e99.","journal-title":"J Clin Psychiatry"},{"key":"2800_CR51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/archpsyc.1971.01750070037005","volume":"24","author":"WH McGlothlin","year":"1971","unstructured":"McGlothlin WH, Arnold DO. LSD revisited: a ten-year follow-up of medical LSD use. Arch Gen Psychiatry. 1971;24:35\u201349.","journal-title":"Arch Gen Psychiatry"},{"key":"2800_CR52","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/archpsyc.1983.01790070067008","volume":"40","author":"MM Vardy","year":"1983","unstructured":"Vardy MM, Kay SR. LSD psychosis or LSD-induced schizophrenia?: a multimethod inquiry. Arch Gen Psychiatry. 1983;40:877\u201383.","journal-title":"Arch Gen Psychiatry"},{"key":"2800_CR53","unstructured":"Lima FAS, T\u00f3foli LF, Labate B, Jungaberle H. An epidemiological surveillance system by the UDV: mental health recommendations concerning the religous use of hoasca 2011."},{"key":"2800_CR54","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1176\/ajp.128.6.695","volume":"128","author":"RL Bergman","year":"1971","unstructured":"Bergman RL. Navajo peyote use: Its apparent safety. Am J Psychiatry. 1971;128:695\u20139.","journal-title":"Am J Psychiatry"},{"key":"2800_CR55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2045125316689030","volume":"7","author":"R Dos Santos","year":"2017","unstructured":"Dos Santos R, Bouso JC, Hallak J. Ayahuasca, dimethyltryptamine, and psychosis: A systematic review of human studies. Ther Adv Psychopharmacol. 2017;7:1\u201317.","journal-title":"Ther Adv Psychopharmacol"},{"key":"2800_CR56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1159\/000059383","volume":"8","author":"MA Landabaso","year":"2002","unstructured":"Landabaso MA, Iraurgi I, Jim\u00e9nez-Lerma JM, Calle R, Sanz J, Guti\u00e9rrez-Fraile M. Ecstasy-induced psychotic disorder: six-month follow-up study. Eur Addict Res. 2002;8:133\u201340.","journal-title":"Eur Addict Res"},{"key":"2800_CR57","doi-asserted-by":"crossref","first-page":"e63972","DOI":"10.1371\/journal.pone.0063972","volume":"8","author":"TS Krebs","year":"2013","unstructured":"Krebs TS, Johansen P-\u00d8. Psychedelics and mental health: a population study. PLoS One. 2013;8:e63972.","journal-title":"PLoS One"},{"key":"2800_CR58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0013-7006(05)82367-X","volume":"31","author":"FJ Bayl\u00e9","year":"2005","unstructured":"Bayl\u00e9 FJ, Misdrahi D, Llorca PM, Lan\u00e7on C, Olivier V, Quintin P, et al. [Acute schizophrenia concept and definition: investigation of a French psychiatrist population]. Encephale. 2005;31:10\u20137.","journal-title":"Encephale"},{"key":"2800_CR59","doi-asserted-by":"crossref","unstructured":"Johansen P-\u00d8, Krebs T. Psychedelics not linked to mental health problems or suicidal behavior: A population study. J Psychopharmacol. 2015;29.","DOI":"10.1177\/0269881114568039"},{"key":"2800_CR60","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1176\/ajp.124.11.1483","volume":"124","author":"JT Ungerleider","year":"1968","unstructured":"Ungerleider JT, Fisher DD, Fuller M, Caldwell A. The \u2018bad trip\u2019\u2013the etiology of the adverse LSD reaction. Am J Psychiatry. 1968;124:1483\u201390.","journal-title":"Am J Psychiatry"},{"key":"2800_CR61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/070674377301800413","volume":"18","author":"P Hays","year":"1973","unstructured":"Hays P, Tilley JR. The differences between LSD psychosis and schizophrenia. Can Psychiatr Assoc J. 1973;18:331\u20133.","journal-title":"Can Psychiatr Assoc J"},{"key":"2800_CR62","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3390\/ijerph9072283","volume":"9","author":"F Rugani","year":"2012","unstructured":"Rugani F, Bacciardi S, Rovai L, Pacini M, Maremmani AGI, Deltito J, et al. Symptomatological features of patients with and without Ecstasy use during their first psychotic episode. Int J Environ Res Public Health. 2012;9:2283\u201392.","journal-title":"Int J Environ Res Public Health"},{"key":"2800_CR63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1192\/bjp.100.418.129","volume":"100","author":"B Sloane","year":"1954","unstructured":"Sloane B, Doust LW. Psychophysiological investigations in experimental psychoses: results of the exhibition of d-lysergic acid diethylamide to psychiatric patients. J Ment Sci. 1954;100:129\u201344.","journal-title":"J Ment Sci"},{"key":"2800_CR64","doi-asserted-by":"crossref","unstructured":"Schmid Y, Enzler F, Gasser P, Grouzmann E, Preller K, Vollenweider F, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78:544\u201353.","DOI":"10.1016\/j.biopsych.2014.11.015"},{"key":"2800_CR65","doi-asserted-by":"publisher","unstructured":"Preller K, Burt J, Ji JL, Schleifer C, Adkinson B, Staempfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. Elife. 2018;7. https:\/\/doi.org\/10.7554\/eLife.35082.","DOI":"10.7554\/eLife.35082"},{"key":"2800_CR66","first-page":"1","volume":"53","author":"I Wiessner","year":"2021","unstructured":"Wiessner I, Falchi M, Palhano-Fontes F, Feilding A, Ribeiro S, T\u00f3foli L. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Psychol Med. 2021;53:1\u201315.","journal-title":"Psychol Med"},{"key":"2800_CR67","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00408109","volume":"1","author":"H Isbell","year":"1959","unstructured":"Isbell H. Comparison of the reactions induced by psilocybin and LSD-25 in man. Psychopharmacologia. 1959;1:29\u201338.","journal-title":"Psychopharmacologia"},{"key":"2800_CR68","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF00412109","volume":"3","author":"AB Wolbach","year":"1962","unstructured":"Wolbach AB, Miner EJ, Isbell H. Comparison of psilocin with psilocybin, mescaline and LSD-25. Psychopharmacologia. 1962;3:219\u201323.","journal-title":"Psychopharmacologia"},{"key":"2800_CR69","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol. 2011;25:439\u201352.","journal-title":"J Psychopharmacol"},{"key":"2800_CR70","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med. 2021;384:1402\u201311.","journal-title":"N Engl J Med"},{"key":"2800_CR71","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78:481\u20139.","journal-title":"JAMA Psychiatry"},{"key":"2800_CR72","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX. Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology (Berl). 2004;172:145\u201356.","journal-title":"Psychopharmacology (Berl)"},{"key":"2800_CR73","first-page":"97","volume":"14","author":"RV Shirvaikar","year":"1966","unstructured":"Shirvaikar RV, Kelkar YW. Therapeutic trial of lysergic Acid diethylamide (LSD) and thioridazine in chronic schizophrenia. Neurol India. 1966;14:97\u2013101.","journal-title":"Neurol India"},{"key":"2800_CR74","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/15563650903586745","volume":"48","author":"SD Carstairs","year":"2010","unstructured":"Carstairs SD, Cantrell FL. Peyote and mescaline exposures: a 12-year review of a statewide poison center database. Clin Toxicol (Phila). 2010;48:350\u20133.","journal-title":"Clin Toxicol (Phila)"},{"key":"2800_CR75","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","volume":"25","author":"E Studerus","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25:1434\u201352.","journal-title":"J Psychopharmacol"},{"key":"2800_CR76","unstructured":"Baker E LSD psychotherapy LSD psycho-exploration: three reports. In: Bobbs-Merrill, editor. use LSD Psychother. Alcohol., Indianapolis: Abramson HA; 1967. p. 191\u2013207."},{"key":"2800_CR77","unstructured":"Leuner H Present state of psycholytic therapy and its possibilities. In: AH, Abramson, editors. 2nd Int. Conf. Use LSD Psychother. Alcohol., Amityville: The Bobbs-Merrill Co. Inc. 1965."},{"key":"2800_CR78","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1192\/bjp.118.543.229","volume":"118","author":"N Malleson","year":"1971","unstructured":"Malleson N. Acute Adverse Reactions to Lsd in Clinical and Experimental use in the United Kingdom. Br J Psychiatry. 1971;118:229\u201330.","journal-title":"Br J Psychiatry"},{"key":"2800_CR79","first-page":"87","volume":"88","author":"SJ Novak","year":"1997","unstructured":"Novak SJ. LSD before Leary. Sidney Cohen\u2019s critique of 1950s psychedelic drug research. Isis; an Int Rev Devoted to Hist Sci Its Cult Influ. 1997;88:87\u2013110.","journal-title":"Isis; an Int Rev Devoted to Hist Sci Its Cult Influ."},{"key":"2800_CR80","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1176\/appi.ajp.2017.17020223","volume":"175","author":"MSK Starzer","year":"2018","unstructured":"Starzer MSK, Nordentoft M, Hjorth\u00f8j C. Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis. Am J Psychiatry. 2018;175:343\u201350.","journal-title":"Am J Psychiatry"},{"key":"2800_CR81","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1176\/appi.ajp.22010076","volume":"180","author":"EB Rognli","year":"2023","unstructured":"Rognli EB, Heiberg IH, Jacobsen BK, H\u00f8ye A, Bramness JG. Transition from substance-induced psychosis to schizophrenia spectrum disorder or bipolar disorder. Am J Psychiatry. 2023;180:437\u201344.","journal-title":"Am J Psychiatry"},{"key":"2800_CR82","first-page":"1200","volume":"91","author":"EF Baker","year":"1964","unstructured":"Baker EF. The use of Lysergic acid diethylamide (LSD) in psychotherapy. Can Med Assoc J. 1964;91:1200\u20132.","journal-title":"Can Med Assoc J"},{"key":"2800_CR83","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.mcna.2018.02.010","volume":"102","author":"R Graddy","year":"2018","unstructured":"Graddy R, Buresh ME, Rastegar DA. New and Emerging Illicit Psychoactive Substances. Med Clin North Am. 2018;102:697\u2013714.","journal-title":"Med Clin North Am"},{"key":"2800_CR84","doi-asserted-by":"crossref","unstructured":"Langs RJ, Barr HL Lysergic acid diethylamide (lsd-25) and schizophrenic reactions. J Nerv Ment Dis. 1968;147.","DOI":"10.1097\/00005053-196808000-00008"},{"key":"2800_CR85","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1017\/S0033291721002531","volume":"53","author":"I Wie\u00dfner","year":"2023","unstructured":"Wie\u00dfner I, Falchi M, Palhano-Fontes F, Feilding A, Ribeiro S, T\u00f3foli LF. LSD, madness and healing: Mystical experiences as possible link between psychosis model and therapy model. Psychol Med. 2023;53:1151\u201365.","journal-title":"Psychol Med"},{"key":"2800_CR86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnbeh.2011.00001","volume":"5","author":"A Paparelli","year":"2011","unstructured":"Paparelli A, Di Forti M, Morrison PD, Murray RM. Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at more obvious sources of light. Front Behav Neurosci. 2011;5:1.","journal-title":"Front Behav Neurosci"},{"key":"2800_CR87","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2728","volume":"35","author":"L Orsolini","year":"2020","unstructured":"Orsolini L, Chiappini S, Papanti D, Latini R, Volpe U, Fornaro M, et al. How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy. Hum Psychopharmacol. 2020;35:e2728.","journal-title":"Hum Psychopharmacol"},{"key":"2800_CR88","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1177\/02698811221131997","volume":"37","author":"E Morton","year":"2023","unstructured":"Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of \u2018magic mushroom\u2019 consumption. J Psychopharmacol. 2023;37:49\u201360.","journal-title":"J Psychopharmacol"},{"key":"2800_CR89","doi-asserted-by":"publisher","unstructured":"Honk L, Stenfors CUD, Goldberg SB, Hendricks PS, Osika W, Dourron HM, et al. Longitudinal associations between psychedelic use and psychotic symptoms in the United States and United Kingdom. J Affect Disord. 2024. https:\/\/doi.org\/10.1016\/j.jad.2024.01.197.","DOI":"10.1016\/j.jad.2024.01.197"},{"key":"2800_CR90","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","volume":"236","author":"MC Mithoefer","year":"2019","unstructured":"Mithoefer MC, Feduccia AA, Jerome L, Mithoefer A, Wagner M, Walsh Z, et al. MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology (Berl). 2019;236:2735\u201345.","journal-title":"Psychopharmacology (Berl)"},{"key":"2800_CR91","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"FX Vollenweider","year":"2010","unstructured":"Vollenweider FX, Kometer M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci. 2010;11:642\u201351.","journal-title":"Nat Rev Neurosci"},{"key":"2800_CR92","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/0269881121992676","volume":"35","author":"T Hirschfeld","year":"2021","unstructured":"Hirschfeld T, Schmidt TT. Dose-response relationships of psilocybin-induced subjective experiences in humans. J Psychopharmacol. 2021;35:384\u201397.","journal-title":"J Psychopharmacol"},{"key":"2800_CR93","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/ijnp\/pyac074","volume":"26","author":"JJ Gattuso","year":"2023","unstructured":"Gattuso JJ, Perkins D, Ruffell S, Lawrence AJ, Hoyer D, Jacobson LH, et al. Default Mode Network Modulation by Psychedelics: A Systematic Review. Int J Neuropsychopharmacol. 2023;26:155\u201388.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2800_CR94","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tics.2022.11.006","volume":"27","author":"C Timmermann","year":"2023","unstructured":"Timmermann C, Bauer PR, Gosseries O, Vanhaudenhuyse A, Vollenweider F, Laureys S, et al. A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics. Trends Cogn Sci. 2023;27:139\u201359.","journal-title":"Trends Cogn Sci"},{"key":"2800_CR95","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.adf0435","volume":"379","author":"MV Vargas","year":"2023","unstructured":"Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379:700\u20136.","journal-title":"Science"},{"key":"2800_CR96","doi-asserted-by":"crossref","unstructured":"de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Front Psychiatry. 2021;12:72606.","DOI":"10.3389\/fpsyt.2021.724606"},{"key":"2800_CR97","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"Moliner R","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032\u201341.","journal-title":"Nat Neurosci"},{"key":"2800_CR98","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41380-023-02312-8","volume":"29","author":"U Heresco-Levy","year":"2024","unstructured":"Heresco-Levy U, Lerer B. Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders. Mol Psychiatry. 2024;29:146\u201352.","journal-title":"Mol Psychiatry"},{"key":"2800_CR99","volume":"13","author":"K Ko","year":"2022","unstructured":"Ko K, Knight G, Rucker JJ, Cleare AJ. Psychedelics, mystical experience, and therapeutic efficacy: a systematic review. Front Psychiatry. 2022;13:917199.","journal-title":"Front Psychiatry"},{"key":"2800_CR100","doi-asserted-by":"crossref","unstructured":"Winkelman MJ. The mechanisms of psychedelic visionary experiences: hypotheses from evolutionary psychology. Front Neurosci. 2017;11:539.","DOI":"10.3389\/fnins.2017.00539"},{"key":"2800_CR101","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/cpt.3050","volume":"114","author":"RH Dworkin","year":"2023","unstructured":"Dworkin RH, McDermott MP, Nayak SM, Strain EC. Psychedelics and psychotherapy: is the whole greater than the sum of its parts? Clin Pharmacol Ther. 2023;114:1166\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"2800_CR102","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1089\/psymed.2023.0028","volume":"2","author":"A Wen","year":"2023","unstructured":"Wen A, Singhal N, Jones BDM, Zeifman RJ, Mehta S, Shenasa MA, et al. A systematic review of study design and placebo controls in psychedelic research. Psychedelic Med. 2023;2:15\u201324.","journal-title":"Psychedelic Med"},{"key":"2800_CR103","unstructured":"Busch A, Johnson W. L.S.D. 25 as an aid in psychotherapy; preliminary report of a new drug. Dis Nerv Syst. 1950;11:241\u20133."},{"key":"2800_CR104","first-page":"5","volume":"7","author":"U De Giacomo","year":"1951","unstructured":"De Giacomo U. La catatonie toxique exp\u00e9rimentale. Acta Neurol (Napoli). 1951;7:5\u201310.","journal-title":"Acta Neurol (Napoli)"},{"key":"2800_CR105","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1136\/bmj.2.4727.317","volume":"2","author":"W Mayer-Gross","year":"1951","unstructured":"Mayer-Gross W. Experimental psychoses and other mental abnormalities produced by drugs. Br Med J. 1951;2:317\u201321.","journal-title":"Br Med J."},{"key":"2800_CR106","first-page":"85","volume":"14","author":"S Katzenelbogen","year":"1953","unstructured":"Katzenelbogen S, Fang AD. Narcosynthesis effects of sodium amytal, methedrine and L.S.D-25. Dis Nerv Syst. 1953;14:85\u20138.","journal-title":"Dis Nerv Syst."},{"key":"2800_CR107","doi-asserted-by":"crossref","unstructured":"Cholden LS, Kurland A, Savage C. Clinical reactions and tolerance to LSD in chronic schizophrenia. J Nerv Ment Dis. 1955;122.","DOI":"10.1097\/00005053-195509000-00001"},{"key":"2800_CR108","doi-asserted-by":"crossref","unstructured":"Abramson HA. The use of LSD in psychotherapy: transactions of a conference on D-lysergic acid diethylamide (LSD-25). April 22, 23 and 24, 1959, Princeton, NJ: Josiah Macy, Jr. Foundation; 1960.","DOI":"10.1097\/00006842-196107000-00022"},{"key":"2800_CR109","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archpsyc.1962.01710210019003","volume":"6","author":"AM Freedman","year":"1962","unstructured":"Freedman AM, Ebin EVAV, Wilson EA. Autistic schizophrenic children: an experiment in the use of D-Lysergic acid diethylamide (LSD-25). Arch Gen Psychiatry. 1962;6:203\u201313.","journal-title":"Arch Gen Psychiatry"},{"key":"2800_CR110","unstructured":"Fischer G, Castile D. An investigation to determine the therapeutic effectiveness of LSD-25 and psilocybin on hospitalized severely emotionally disturbed children. Purdue University Archives and Special Collections; 1963."},{"key":"2800_CR111","doi-asserted-by":"publisher","unstructured":"Bender L, Goldschmidt L, Sankar DVS, Freedman AM. Treatment of autistic schizophrenic children with LSD-25 and UML-491 BT\u2014recent advances in biological psychiatry: Volume IV: The Proceedings of the Sixteenth Annual Convention and Scientific Program of the Society of Biological Psychiatry, Atlantic City. In: Wortis J, editor. Springer US; 1962. p. 170\u20139. https:\/\/doi.org\/10.1007\/978-1-4684-8306-2_17.","DOI":"10.1007\/978-1-4684-8306-2_17"},{"key":"2800_CR112","first-page":"43","volume":"7","author":"L Bender","year":"1966","unstructured":"Bender L. D-lysergic acid in the treatment of the biological features of childhood schizophrenia. Dis Nerv Syst. 1966;7:43\u20136.","journal-title":"Dis Nerv Syst."},{"key":"2800_CR113","first-page":"1849","volume":"67","author":"M Blumenfield","year":"1967","unstructured":"Blumenfield M, Glickman L. Ten months experience with LSD users admitted to county psychiatric receiving hospital. N Y State J Med. 1967;67:1849\u201353.","journal-title":"N Y State J Med"},{"key":"2800_CR114","first-page":"327","volume":"209","author":"K Dewhurst","year":"1972","unstructured":"Dewhurst K, Hatrick JA. Differential diagnosis and treatment of lysergic acid diethylamide induced psychosis. Practitioner. 1972;209:327\u201332.","journal-title":"Practitioner"},{"key":"2800_CR115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/070674378102600113","volume":"26","author":"A Roy","year":"1981","unstructured":"Roy A. LSD and onset of schizophrenia. Can J Psychiatry. 1981;26:64\u20135.","journal-title":"Can J Psychiatry."},{"key":"2800_CR116","doi-asserted-by":"crossref","first-page":"469","DOI":"10.15288\/qjsa.1966.27.469","volume":"27","author":"RG Smart","year":"1966","unstructured":"Smart RG, Storm T, Baker EF, Solursh L. A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. Q J Stud Alcohol. 1966;27:469\u201382.","journal-title":"Q J Stud Alcohol"},{"key":"2800_CR117","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/15504263.2014.906155","volume":"10","author":"S Lev-Ran","year":"2014","unstructured":"Lev-Ran S, Feingold D, Frenkel A, Lerner AG. Clinical characteristics of individuals with schizophrenia and hallucinogen persisting perception disorder: a preliminary investigation. J Dual Diagn. 2014;10:79\u201383.","journal-title":"J Dual Diagn."},{"key":"2800_CR118","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ajad.12204","volume":"24","author":"S Lev-Ran","year":"2015","unstructured":"Lev-Ran S, Feingold D, Rudinski D, Katz S, Arturo LG. Schizophrenia and hallucinogen persisting perception disorder: a clinical investigation. Am J Addict. 2015;24:197\u20139.","journal-title":"Am J Addict."},{"key":"2800_CR119","doi-asserted-by":"crossref","first-page":"932","DOI":"10.15288\/qjsa.1970.31.932","volume":"31","author":"M Tomsovic","year":"1970","unstructured":"Tomsovic M, Edwards RV. Lysergide treatment of schizophrenic and nonschizophrenic alcoholics: a controlled evaluation. Q J Stud Alcohol. 1970;31:932\u201349.","journal-title":"Q J Stud Alcohol"},{"key":"2800_CR120","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202:513\u201320.","journal-title":"J Nerv Ment Dis"},{"key":"2800_CR121","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.biopsych.2014.11.015","volume":"78","author":"Y Schmid","year":"2015","unstructured":"Schmid Y, et al. Acute effects of lysergic acid diethylamide in healthy subjects. Biol Psychiatry. 2015;78:544\u201353.","journal-title":"Biol Psychiatry"},{"key":"2800_CR122","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-61169-x","volume":"10","author":"DF Jim\u00e9nez-Garrido","year":"2020","unstructured":"Jim\u00e9nez-Garrido DF, et al. Effects of ayahuasca on mental health and quality of life in na\u00efve users: a longitudinal and cross-sectional study combination. Sci Rep. 2020;10:4075.","journal-title":"Sci Rep."},{"key":"2800_CR123","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0028-1094512","volume":"10","author":"P Bickel","year":"1977","unstructured":"Bickel P, Dittrich A, Schopf J. Effekte von N,N-dimethyltryptamin (DMT) auf psychotizismus-tests. Pharmacopsychiatry. 1977;10:10\u201314.","journal-title":"Pharmacopsychiatry"},{"key":"2800_CR124","doi-asserted-by":"crossref","unstructured":"Bouso JC, et al. Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. Eur Neuropsychopharmacol. 2015;25:483\u201392.","DOI":"10.1016\/j.euroneuro.2015.01.008"},{"key":"2800_CR125","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/archpsyc.1994.03950020022002","volume":"51","author":"RJ Strassman","year":"1994","unstructured":"Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry. 1994;51:98\u2013108.","journal-title":"Arch Gen Psychiatry"},{"key":"2800_CR126","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/JCP.0000000000001428","volume":"41","author":"RG Dos Santos","year":"2021","unstructured":"Dos Santos RG, et al. Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: a pilot, proof-of-concept, randomized, placebo-controlled trial. J Clin Psychopharmacol. 2021;41:540\u201350.","journal-title":"J Clin Psychopharmacol"},{"key":"2800_CR127","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S0893-133X(96)00246-1","volume":"16","author":"FX Vollenweider","year":"1997","unstructured":"vollenweider, F. X. et al. Positron emission tomography and fluorodeoxyglucose sturies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacol. 1997;16;357\u201372.","journal-title":"Neuropsychopharmacol"},{"key":"2800_CR128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2174\/1874473708666150107121331","volume":"7","author":"A Garcia-Romeu","year":"2014","unstructured":"Garcia-Romeu A, Griffiths RR, Johnson MW. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Curr Drug Abus Rev. 2014;7:157\u201364.","journal-title":"Curr Drug Abus Rev"},{"key":"2800_CR129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68:71\u20138.","journal-title":"Arch Gen Psychiatry"},{"key":"2800_CR130","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol. 2016;30:1181\u201397.","journal-title":"J Psychopharmacol."},{"key":"2800_CR131","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30:1165\u201380.","journal-title":"J Psychopharmacol."},{"key":"2800_CR132","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamapsychiatry.2022.2096","volume":"79","author":"MP Bogenschutz","year":"2022","unstructured":"Bogenschutz MP, et al. Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2022;79:953\u201362.","journal-title":"JAMA Psychiatry"},{"key":"2800_CR133","doi-asserted-by":"crossref","first-page":"101809","DOI":"10.1016\/j.eclinm.2022.101809","volume":"56","author":"R von Rotz","year":"2023","unstructured":"von Rotz R, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2023;56:101809.","journal-title":"EClinicalMedicine"},{"key":"2800_CR134","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/02791072.2008.10400637","volume":"40","author":"JC Bouso","year":"2008","unstructured":"Bouso JC, Doblin R, Farr\u00e9 M, Alc\u00e1zar MA, G\u00f3mez-Jarabo G. MDMA-assisted psychotherapy using low doses in a small sample of women with chronic posttraumatic stress disorder. J Psychoact Drugs. 2008;40:225\u201336.","journal-title":"J Psychoact Drugs"},{"key":"2800_CR135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (\u00b1 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). J Psychopharmacol. 2013;27:40\u201352.","journal-title":"J Psychopharmacol."},{"key":"2800_CR136","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","volume":"235","author":"AL Danforth","year":"2018","unstructured":"Danforth AL, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacol. (Berl). 2018;235:3137\u201348.","journal-title":"Psychopharmacol. (Berl)"},{"key":"2800_CR137","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1177\/0269881118806297","volume":"32","author":"GM Ot\u2019alora","year":"2018","unstructured":"Ot\u2019alora GM, et al. 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized phase 2 controlled trial. J Psychopharmacol. 2018;32:1295\u2013307.","journal-title":"J Psychopharmacol"},{"key":"2800_CR138","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","volume":"237","author":"L Jerome","year":"2020","unstructured":"Jerome L, et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacol. (Berl). 2020;237:2485\u201397.","journal-title":"Psychopharmacol. (Berl)"},{"key":"2800_CR139","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025\u201333.","journal-title":"Nat Med."},{"key":"2800_CR140","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/jts.22696","volume":"34","author":"L Ponte","year":"2021","unstructured":"Ponte L, et al. Sleep quality improvements after MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder. J Trauma Stress. 2021;34:851\u201363.","journal-title":"J Trauma Stress"},{"key":"2800_CR141","doi-asserted-by":"crossref","DOI":"10.1186\/s40337-023-00773-4","volume":"11","author":"TD Brewerton","year":"2023","unstructured":"Brewerton TD, Gavidia I, Suro G, Perlman MM. Eating disorder patients with and without PTSD treated in residential care: discharge and 6-month follow-up results. J Eat Disord. 2023;11:48.","journal-title":"J Eat Disord"},{"key":"2800_CR142","doi-asserted-by":"crossref","first-page":"109356","DOI":"10.1016\/j.drugalcdep.2022.109356","volume":"233","author":"CR Nicholas","year":"2022","unstructured":"Nicholas CR, et al. The effects of MDMA-assisted therapy on alcohol and substance use in a phase 3 trial for treatment of severe PTSD. Drug Alcohol Depend. 2022;233:109356.","journal-title":"Drug Alcohol Depend"},{"key":"2800_CR143","unstructured":"Pacey I. Randomized, double-blind, controlled of MDMA-assisted psychotherapy in 12 subjects with PTSD. NCT01958593. Lykos Therapeutics. 2017. https:\/\/clinicaltrials.gov\/study\/NCT01958593."},{"key":"2800_CR144","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75706-1","volume":"10","author":"PE Wolfson","year":"2020","unstructured":"Wolfson PE, et al. MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep. 2020;10:20442.","journal-title":"Sci Rep."},{"key":"2800_CR145","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1176\/ajp.125.10.1352","volume":"125","author":"LEOE Hollister","year":"1969","unstructured":"Hollister LEOE, Shelton J, Krieger G. A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetamine in alcoholics. Am J Psychiatry. 1969;125:1352\u201357.","journal-title":"Am J Psychiatry"},{"key":"2800_CR146","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1017\/S0033291700042938","volume":"4","author":"WR Breakey","year":"1974","unstructured":"Breakey WR, Goodell H, Lorenz PC, McHugh PR. Hallucinogenic drugs as precipitants of schizophrenia. Psychol Med. 1974;4:255\u201361.","journal-title":"Psychol Med."},{"key":"2800_CR147","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1176\/jnp.8.3.262","volume":"8","author":"NN Boutros","year":"1996","unstructured":"Boutros NN, Bowers MBJ. Chronic substance-induced psychotic disorders: state of the literature. J Neuropsychiatry Clin Neurosci. 1996;8:262\u20139.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2800_CR148","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1089\/cap.2006.16.767","volume":"16","author":"G Shoval","year":"2006","unstructured":"Shoval G, et al. Substance use, suicidality, and adolescent-onset schizophrenia: an Israeli 10-year retrospective study. J Child Adolesc Psychopharmacol. 2006;16:767\u201375.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"2800_CR149","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1177\/0269881113513851","volume":"28","author":"PS Hendricks","year":"2014","unstructured":"Hendricks PS, Clark CB, Johnson MW, Fontaine KR, Cropsey KL. Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. J Psychopharmacol. 2014;28:62\u20136.","journal-title":"J Psychopharmacol"},{"key":"2800_CR150","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1177\/0269881114565653","volume":"29","author":"PS Hendricks","year":"2015","unstructured":"Hendricks PS, Thorne CB, Clark CB, Coombs DW, Johnson MW. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J Psychopharmacol. 2015;29:280\u20138.","journal-title":"J Psychopharmacol."},{"key":"2800_CR151","volume":"16","author":"OM Vallersnes","year":"2016","unstructured":"Vallersnes OM, et al. Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry. 2016;16:293.","journal-title":"BMC Psychiatry"},{"key":"2800_CR152","doi-asserted-by":"crossref","first-page":"e0293349","DOI":"10.1371\/journal.pone.0293349","volume":"18","author":"J Evans","year":"2023","unstructured":"Evans J, et al. Extended difficulties following the use of psychedelic drugs: a mixed methods study. PLoS ONE. 2023;18:e0293349.","journal-title":"PLoS ONE"},{"key":"2800_CR153","doi-asserted-by":"publisher","unstructured":"Simonsson O, et al. Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom. J. Psychopharmacol. 2023. https:\/\/doi.org\/10.1177\/02698811231218931.","DOI":"10.1177\/02698811231218931"},{"key":"2800_CR154","first-page":"1214","volume":"97","author":"RG Smart","year":"1967","unstructured":"Smart RG, Bateman K. Unfavourable reactions to LSD: a review and analysis of the available case reports. Can Med Assoc J. 1967;97:1214\u201321.","journal-title":"Can Med Assoc J."},{"key":"2800_CR155","unstructured":"Leuner H. Present state of psycholytic therapy and its possibilities. In: Abramson AH, editor. 2nd International Conference on the Use of LSD in Psychotherapy and Alcoholism. Amityville, N.Y.: The Bobbs-Merrill Co. Inc.; 1965."},{"key":"2800_CR156","first-page":"723","volume":"114","author":"LH Panhuysen","year":"1970","unstructured":"Panhuysen LH. Undesirable side effects of LSD administration. Ned Tijdschr Geneeskd. 1970;114:723\u20137.","journal-title":"Ned Tijdschr Geneeskd."},{"key":"2800_CR157","doi-asserted-by":"crossref","unstructured":"De Gregorio D, Comai S, Posa L, Gobbi G. d-lysergic acid diethylamide (LSD) as a model of psychosis: mechanism of action and pharmacology. Int J Mol Sci. 2016;17.","DOI":"10.3390\/ijms17111953"},{"key":"2800_CR158","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.mehy.2004.11.005","volume":"64","author":"MS Jacob","year":"2005","unstructured":"Jacob MS, Presti DE. Endogenous psychoactive tryptamines reconsidered: an anxiolytic role for dimethyltryptamine. Med Hypotheses. 2005;64:930\u20137.","journal-title":"Med Hypotheses"},{"key":"2800_CR159","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00702-014-1329-5","volume":"122","author":"D Grammenos","year":"2015","unstructured":"Grammenos D, Barker SA. On the transmethylation hypothesis: stress, N,N-dimethyltryptamine, and positive symptoms of psychosis. J Neural Transm. 2015;122:733\u20139.","journal-title":"J Neural Transm"},{"key":"2800_CR160","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1360-0443.2006.01652.x","volume":"102","author":"RS Gable","year":"2007","unstructured":"Gable RS. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction. 2007;102:24\u201334.","journal-title":"Addiction"},{"key":"2800_CR161","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/10550887.2019.1673655","volume":"37","author":"VY Skryabin","year":"2018","unstructured":"Skryabin VY, Vinnikova M, Nenastieva A, Alekseyuk V. Hallucinogen persisting perception disorder: A literature review and three case reports. J Addict Dis. 2018;37:268\u201378.","journal-title":"J Addict Dis."},{"key":"2800_CR162","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0378-4274(99)00219-2","volume":"112\u2013113","author":"P McGuire","year":"2000","unstructured":"McGuire P. Long term psychiatric and cognitive effects of MDMA use. Toxicol Lett. 2000;112\u2013113:153\u20136.","journal-title":"Toxicol Lett."},{"key":"2800_CR163","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hup.350","volume":"16","author":"K Soar","year":"2001","unstructured":"Soar K, Turner JJD, Parrott AC. Psychiatric disorders in Ecstasy (MDMA) users: a literature review focusing on personal predisposition and drug history. Hum Psychopharmacol. 2001;16:641\u20135.","journal-title":"Hum Psychopharmacol."},{"key":"2800_CR164","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcph.1995","volume":"62","author":"KW Smith","year":"2022","unstructured":"Smith KW, Sicignano DJ, Hernandez AV, White CM. MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with meta-analysis. J Clin Pharmacol. 2022;62:463\u201371.","journal-title":"J Clin Pharmacol."},{"key":"2800_CR165","first-page":"44","volume":"1","author":"RE Mogar","year":"1969","unstructured":"Mogar RE, Aldrich RW. The use of psychedelic agents with autistic schizophrenic children. Behav Neuropsychiatry. 1969;1:44\u201350.","journal-title":"Behav Neuropsychiatry"},{"key":"2800_CR166","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00005053-197304000-00003","volume":"156","author":"GS Glass","year":"1973","unstructured":"Glass GS. Psychedelic drugs, stress, and the ego. J Nerv Ment Dis. 1973;156:232\u201341.","journal-title":"J Nerv Ment Dis."},{"key":"2800_CR167","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/02791072.1977.10472036","volume":"9","author":"OL McCabe","year":"1977","unstructured":"McCabe OL. Psychedelic drug crises: toxicity and therapeutics. J Psychedelic Drugs. 1977;9:107\u201321.","journal-title":"J Psychedelic Drugs"},{"key":"2800_CR168","doi-asserted-by":"crossref","first-page":"224413","DOI":"10.1103\/PhysRevB.77.224413","volume":"77","author":"M Hermele","year":"2008","unstructured":"Hermele M, Ran Y, Lee PA, Wen X-G. Properties of an algebraic spin liquid on the kagome lattice. Phys Rev B. 2008;77:224413.","journal-title":"Phys Rev B"},{"key":"2800_CR169","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/02791072.2019.1593559","volume":"51","author":"A Trope","year":"2019","unstructured":"Trope A, et al. Psychedelic-assisted group therapy: a systematic review. J Psychoact Drugs. 2019;51:174\u201388.","journal-title":"J Psychoact Drugs"},{"key":"2800_CR170","first-page":"92","volume":"39","author":"AG Lerner","year":"2002","unstructured":"Lerner AG, et al. Flashback and Hallucinogen Persisting Perception Disorder: clinical aspects and pharmacological treatment approach. Isr J Psychiatry Relat Sci. 2002;39:92\u20139.","journal-title":"Isr J Psychiatry Relat Sci."},{"key":"2800_CR171","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.euroneuro.2014.05.008","volume":"24","author":"RPW Litjens","year":"2014","unstructured":"Litjens RPW, Brunt TM, Alderliefste G-J, Westerink RHS. Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases. Eur Neuropsychopharmacol. 2014;24:1309\u201323.","journal-title":"Eur Neuropsychopharmacol."},{"key":"2800_CR172","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0376-8716(02)00306-X","volume":"69","author":"JH Halpern","year":"2003","unstructured":"Halpern JH, Pope HGJ. Hallucinogen persisting perception disorder: what do we know after 50 years. Drug Alcohol Depend. 2003;69:109\u201319.","journal-title":"Drug Alcohol Depend"},{"key":"2800_CR173","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fpsyt.2017.00240","volume":"8","author":"L Orsolini","year":"2017","unstructured":"Orsolini L, et al. The \u2018Endless Trip\u2019 among the NPS users: psychopathology and psychopharmacology in the hallucinogen-persisting perception disorder. a systematic review. Front Psychiatry. 2017;8:240.","journal-title":"Front Psychiatry"},{"key":"2800_CR174","doi-asserted-by":"crossref","unstructured":"Martinotti G, et al. Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sci. 2018;8.","DOI":"10.3390\/brainsci8030047"},{"key":"2800_CR175","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14740338.2022.2063273","volume":"21","author":"MA Doyle","year":"2022","unstructured":"Doyle MA, et al. Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment. Expert Opin Drug Saf. 2022;21:733\u201343.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02800-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02800-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02800-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T09:44:03Z","timestamp":1739871843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-024-02800-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":175,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2800"],"URL":"https:\/\/doi.org\/10.1038\/s41380-024-02800-5","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"assertion":[{"value":"1 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CUC has been a consultant and\/or advisor to or has received honoraria from: AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen\/J&J, Karuna, LB Pharma, Lundbeck, MedAvante-ProPhase, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, Pharmabrain, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Tolmar, Vertex, and Viatris. He provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, Denovo, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva. He has received grant support from Janssen and Takeda. He received royalties from UpToDate and is also a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Mindpax, and Quantic. KHP is currently an employee of Boehringer Ingelheim GmBH & CO KG, Chief Scientist and on the Board of Directors of the Heffter Research Institute, and scientific advisor for the MIND Foundation. MaS has received honoraria\/has been a consultant for AbbVie, Angelini, Lundbeck and Otsuka. SK has received advisory board honoraria from Boehringer Ingelheim and royalties for cognitive testing and training software from Schufried. All other authors report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}